Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Close

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Arthritis and Rheumatism|June 7, 2013
Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III studyEduardo F Mysler, Alberto J Spindler, Renato Guzman, et al.
Plos Neglected Tropical Diseases|April 21, 2010
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activityElizabeth R Sharlow, Todd A Lyda, Heidi C Dodson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid ArthritisMichael E Weinblatt, Iain B McInnes, Joel M Kremer, et al.
ACS Chemical Biology|December 17, 2013
Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activityElizabeth R Sharlow, Stephanie Leimgruber, Samantha Murray, et al.
ACS Pharmacology & Translational Science|April 18, 2022
Validation of HDAC8 Inhibitors as Drug Discovery Starting Points to Treat Acute Kidney InjuryKeith Long, Zoe Vaughn, Michael David McDaniels, et al.
Annals of the Rheumatic Diseases|February 19, 2017
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritisGerd R Burmester, Iain B McInnes, Joel Kremer, et al.
Mabs|April 15, 2026
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritisGary P Sims, Lacie Scaletta, John Andrews, et al.
JAMA Oncology|July 17, 2015
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell CarcinomaEliezer M Van Allen, Vivian W Y Lui, Ann Marie Egloff, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Arthritis and Rheumatism|June 7, 2013
Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III studyEduardo F Mysler, Alberto J Spindler, Renato Guzman, et al.
Plos Neglected Tropical Diseases|April 21, 2010
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activityElizabeth R Sharlow, Todd A Lyda, Heidi C Dodson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid ArthritisMichael E Weinblatt, Iain B McInnes, Joel M Kremer, et al.
ACS Chemical Biology|December 17, 2013
Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activityElizabeth R Sharlow, Stephanie Leimgruber, Samantha Murray, et al.
ACS Pharmacology & Translational Science|April 18, 2022
Validation of HDAC8 Inhibitors as Drug Discovery Starting Points to Treat Acute Kidney InjuryKeith Long, Zoe Vaughn, Michael David McDaniels, et al.
Annals of the Rheumatic Diseases|February 19, 2017
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritisGerd R Burmester, Iain B McInnes, Joel Kremer, et al.
Mabs|April 15, 2026
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritisGary P Sims, Lacie Scaletta, John Andrews, et al.
JAMA Oncology|July 17, 2015
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell CarcinomaEliezer M Van Allen, Vivian W Y Lui, Ann Marie Egloff, et al.
Pageof 3